HealthyPhase 1NCT05288829
A Study of a Single Subcutaneous Dose of ALXN1210 in Healthy Adult Participants
A Phase 1 study testing ALXN1210 SC and ALXN1210 IV in people with Healthy, run by Alexion Pharmaceuticals, Inc. at 1 site in United Kingdom.
Trial summary
This study evaluated the safety and tolerability of a single dose of ALXN1210 subcutaneous (SC) compared to ALXN1210 intravenous (IV) in healthy participants and to determine the absolute bioavailability of ALXN1210 SC. Read more about this study
- Who is it for?
- Ages 25 to 55 yearsHealthy volunteers can take part
- Conditions the study is for
- Healthy
- What is being tested?
- ALXN1210 SC and ALXN1210 IV
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 42 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 19 Aug 2016to 18 Jul 2017
- Phase
- Phase 1
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 25 to 55 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Body mass index from 18 through 29.9 kilogram (kg)/square meter, inclusive, and weight between 50 and 100 kg, inclusive.
- QT interval corrected using Fridericia's formula ≤ 450 milliseconds (msec) for males and ≤ 470 msec for females at Screening and prior to dosing on Day 1.
- Was willing and was able to give written informed consent and complied with the study visit schedule.
- Documented vaccination with tetravalent meningococcal conjugate vaccine at least 56 days and not more than 3 years prior to dosing. Documentation must have included a positive serum bactericidal antibody titer to confirm an immune response before study drug administration.
- Vaccination with serogroup B meningococcal vaccine at least 56 days prior to dosing on Day 1, with a booster administered at least 28 days prior to dosing on Day 1, with at least 28 days between the first and second injections.
- Female participants of childbearing potential, if heterosexually active, must use highly effective contraception.
Who cannot join
- Participants who were in intimate and prolonged contact with (defined as living under the same roof or providing personal care to) people younger than 2 years of age or older than 65 years of age, or who were either immunocompromised or had 1 of the following underlying medical conditions: anatomic or functional asplenia (including sickle cell disease); congenital complement, properdin, factor D, or primary antibody deficiencies; acquired complement deficiencies (for example, those receiving eculizumab); or human immunodeficiency virus (HIV).
- Participants who were one of the following: professionals exposed to environments of greater risk for meningococcal disease; research, industrial, and clinical laboratory personnel routinely exposed to Neisseria meningitidis; military personnel during recruit training (military personnel could have been at increased risk of meningococcal infection when accommodated in close quarters); daycare center workers; those living on a college or university campus; and those who planned to travel during the course of the study to or had travelled to endemic areas for meningococcal meningitis (for example, India, Sub-Saharan Africa, or pilgrimage to Saudi Arabia for Hajj) within the past 6 months.
- History of any Neisseria infection.
- History of unexplained, recurrent infection, or infection requiring treatment with systemic antibiotics within 90 days prior to dosing.
- Evidence of HIV infection (HIV-1 or HIV-2 antibody titer).
- Acute or chronic hepatitis B virus infection. Hepatitis B surface antigen (HBsAg) testing was required for all participants prior to enrollment. Participants with positive HBsAg were not enrolled. For participants with negative HBsAg, the following testing algorithm was required: If hepatitis B core antibody (HBcAb) was negative, the participant was eligible to enroll and If HBcAb was positive, the hepatitis B surface antibody (HBsAb) was tested. (If both HBcAb and HBsAb were positive, the participant was eligible to enroll and If HBcAb was positive and HBsAb was negative, the participant was not enrolled.)
Show all 31Show fewer
- Acute or chronic hepatitis C virus infection (evidenced by antibody titer).
- Active systemic viral or fungal infection within 14 days prior to dosing.
- Positive or indeterminate QuantiFERON-TB test which indicated possible tuberculosis (TB) infection.
- History of latent or active TB or exposure to endemic areas within 8 weeks prior to the Screening visit.
- Female participants who are breastfeeding or are heterosexually active and unwilling to practice contraception and are not postmenopausal.
- Positive serum pregnancy test at Screening or on Day -1.
- Serum creatinine greater than the upper limit of normal (ULN) of the reference range of the testing laboratory at Screening or on Day -1.
- Alanine aminotransferase or aspartate aminotransferase > ULN of the reference range of the testing laboratory at Screening or > 1.5*ULN of the reference range of the testing laboratory on Day -1.
- Any of the following hematology results: hemoglobin < 130 grams (g)/liter for males and < 115 g/L for females, hematocrit < 0.37 L/L for males and < 0.33 L/L for females, white blood cell count < 3.0*10^3/microliter (μL), absolute neutrophil count < 2.0*10^3/μL, and platelet count < 150 or > 400*10^3/μL at Screening or on Day -1. Complete blood count clinical laboratory results that were considered clinically relevant and unacceptable by the Investigator at Day -1.
- History of complement deficiency or complement activity below the normal reference range as evaluated by complement alternative pathway enzyme-linked immunosorbent assay at Screening.
- History of malignancy with the exception of a nonmelanoma skin cancer or carcinoma in situ of the cervix that had been treated with no evidence of recurrence.
- Participation in a clinical study within 30 days before initiation of dosing on Day 1 or use of any experimental small-molecule therapy within 30 days prior to dosing on Day 1.
- Participation in more than 1 clinical study of a monoclonal antibody (mAb), or participation in a clinical study of a mAb within the 12 months prior to screening, during which the participants was exposed to the active study drug. Participants who participated in only 1 study of a mAb could have been considered for enrollment if they completed that study more than 12 months prior to screening.
- Prior exposure to ALXN1210.
- Major surgery or hospitalization within 90 days prior to dosing.
- History of allergy to excipients of ALXN1210 (for example, polysorbate 80).
- Documented history of allergy to penicillin or cephalosporin.
- History of significant allergic reaction (for example, anaphylaxis or angioedema) to any product (food, pharmaceutical, etc).
- Smoked > 10 cigarettes daily (former smokers could have been permitted to enroll at the Investigator's discretion).
- Positive urine drug toxicology screen at Screening or on Day -1.
- Donation of plasma within 7 days prior to dosing. Donation or loss (excluding volume drawn at Screening) of more than 50 mL of blood within 30 days prior to dosing or more than 499 mL of blood within 56 days prior to dosing.
- Clinical diagnosis of any autoimmune or rheumatologic disease (for example, systemic lupus erythematosus, and rheumatoid arthritis).
- Immunization with a live-attenuated vaccine 28 days prior to dosing or planned vaccination during the course of the study (except for the vaccination planned per protocol). Immunization with inactivated or recombinant influenza vaccine was permitted.
- Presence of fever (confirmed body temperature > 37.6°C) (for example, a fever associated with a symptomatic viral or bacterial infection) within 14 days prior to dosing.
- Participants with any medical history, conditions, or risks that, in the opinion of the Investigator, could have interfered with the participant's full participation in the study or compliance with the protocol, or could have posed any additional risk for the participant or confounded the assessment of the participant or the outcome of the study.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of a Single Dose of ALXN1210 Administered Subcutaneously Compared to Intravenously in Healthy Subjects
This study evaluated the safety and tolerability of a single dose of ALXN1210 subcutaneous (SC) compared to ALXN1210 intravenous (IV) in healthy participants and to determine the absolute bioavailability of ALXN1210 SC.
Read the detailed description
The participants were randomly assigned in a 2:1 ratio to Cohort 1a in a blinded fashion to receive either a single dose of ALXN1210 SC 400 mg or single dose of placebo SC. The Safety Review Committee (SRC) evaluated the first 48 hours of postdose clinical safety data for participants in Cohort 1a to determine if enrollment into Cohorts 1b or 2 could begin. Following the SRC review, participants were randomly assigned in a 2:1 ratio to either Cohort 1b or Cohort 2. Within Cohort 1b, participants were blinded and further randomly assigned in a 5:1 ratio to receive either a single dose of ALXN1210 SC 400 mg or a single dose of placebo SC, respectively. The participants in Cohort 2 received a single dose of ALXN1210 IV 400 mg in an open-label fashion. Safety, PK, PD, and immunogenicity assessments were performed on the follow-up period after the last dose.
- Conditions
- Healthy
- Being tested
- ALXN1210 SC, ALXN1210 IV, Placebo
- Keywords
- Pharmacokinetics, Pharmacodynamics, ALXN1210, Safety, Immunogenicity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ALXN1210 SCDrug
Also called Ravulizumab, Ultomiris
All doses of ALXN1210 SC were administered by four 100-milligram (mg) SC injections of 1 milliliter (mL) each in the abdominal area. All four 1-mL injections were administered over a 15-minute period with at least 15 minutes between the end of injection in 1 participant and the start of injection in the next participant.
ALXN1210 IVDrug
Also called Ravulizumab, Ultomiris
All doses of ALXN1210 IV were administered by IV infusion, using IV sets with in-line filters, at a maximum rate of 333 mL/hour, excluding interruption for safety or technical reason. There were at least 15 minutes between the end-of-infusion/injection in 1 participant and the start-of infusion/injection in the next participant.
PlaceboDrug
All doses of placebo SC were administered by four 100-mg SC injections of 1 mL each in the abdominal area. All four 1-mL injections were administered over a 15-minute period with at least 15 minutes between the end of injection in 1 participant and the start of injection in the next participant.
| Study group | Role | What they receive |
|---|---|---|
| ALXN1210 SC | Experimental | Participants received ALXN1210 SC. Receives: Drug: ALXN1210 SC |
| ALXN1210 IV | Experimental | Participants received ALXN1210 IV. Receives: Drug: ALXN1210 IV |
| Placebo SC | Placebo comparator | Participants received placebo SC. Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
An adverse event (AE) was defined as any unfavorable and unintended sign (for example, including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product or procedure, whether or not considered related to the medicinal product or procedure, which occurred during the course of the clinical study. TEAEs were defined as AEs with a start date or time on or after the first dose of the study drug. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.
Measured: Baseline up to Day 200
Absolute Bioavailability of ALXN1210 SC
The absolute bioavailability of ALXN1210 SC is reported as the area under the serum concentration versus time curve from time 0 extrapolated to infinity (AUCinf) geometric mean of the ALXN1210 SC group divided by the AUCinf geometric mean of the ALXN1210 IV group*100. Linear mixed model with fixed and random effects for the participant was used.
Measured: Predose , end of infusion (EOI); 30 minutes post EOI; 2, 4, and 8 hours post start of infusion; and from Day 2 up to Day 150
Secondary outcomes (3)
Percent Change From Baseline in Free Complement Protein C5 Concentration At Day 8
Blood samples were collected to determine the percent change in free C5 serum concentration from baseline over time.
Measured: Baseline, Day 8
Percent Change From Baseline In Chicken Red Blood Cell Hemolysis At Day 8
Blood samples were collected to determine the percent change in cRBC from baseline over time.
Measured: Baseline, Day 8
Number of Participants With Positive Antidrug Antibodies (ADAs) to ALXN1210
Blood samples were collected to evaluate antibody response through development of ADAs. The number of participants who developed ADAs (ADA positive) to ALXN1210 were reported in this outcome measure.
Measured: Baseline up to Day 200
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Mar 2022
- Study start19 Aug 2016
- Primary completion18 Jul 2017
- Study completion18 Jul 2017
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for HealthyStudies of the same condition, open and under way.
- More trials run by Alexion Pharmaceuticals, Inc.The sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Care provider
- Enrolment
- 42 participants (actual)
Sponsor and investigators
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05288829
- Sponsor's protocol ID
- ALXN1210-SC-101
- Other IDs
- 2016-001617-24, 2016
- Status last verified
- Jun 2022
- First submitted
- 11 Mar 2022
- Last updated
- 1 May 2023
- Results posted
- Yes, on ClinicalTrials.gov
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Yes: Alexion has a public commitment to allow requests for access to study data and will be supplying a protocol, CSR, and plain language summaries.
Study at a glance
From the registry record, last updated by the sponsor on 1 May 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of a Single Dose of ALXN1210 Administered Subcutaneously Compared to Intravenously in Healthy Subjects
- ClinicalTrials.gov ID
- NCT05288829
- Acronym / sponsor ID
- ALXN1210-SC-101
- Conditions
- Healthy
- Keywords
- Pharmacokinetics, Pharmacodynamics, ALXN1210, Safety, Immunogenicity
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 42 participants (actual)
- Lead sponsor
- Alexion Pharmaceuticals, Inc.Industry (pharma, biotech, devices)
- Study start
- 19 Aug 2016 (actual)
- Primary completion
- 18 Jul 2017 (actual)
- Study completion
- 18 Jul 2017 (actual)
- First posted
- 21 Mar 2022 (actual)
- Results
- Posted 1 May 2023
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study evaluated the safety and tolerability of a single dose of ALXN1210 subcutaneous (SC) compared to ALXN1210 intravenous (IV) in healthy participants and to determine the absolute bioavailability of ALXN1210 SC.
Detailed description
The participants were randomly assigned in a 2:1 ratio to Cohort 1a in a blinded fashion to receive either a single dose of ALXN1210 SC 400 mg or single dose of placebo SC. The Safety Review Committee (SRC) evaluated the first 48 hours of postdose clinical safety data for participants in Cohort 1a to determine if enrollment into Cohorts 1b or 2 could begin. Following the SRC review, participants were randomly assigned in a 2:1 ratio to either Cohort 1b or Cohort 2. Within Cohort 1b, participants were blinded and further randomly assigned in a 5:1 ratio to receive either a single dose of ALXN1210 SC 400 mg or a single dose of placebo SC, respectively. The participants in Cohort 2 received a single dose of ALXN1210 IV 400 mg in an open-label fashion. Safety, PK, PD, and immunogenicity assessments were performed on the follow-up period after the last dose.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, care provider)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| ALXN1210 SC | Experimental | Drug: ALXN1210 SCParticipants received ALXN1210 SC. |
| ALXN1210 IV | Experimental | Drug: ALXN1210 IVParticipants received ALXN1210 IV. |
| Placebo SC | Placebo comparator | Drug: PlaceboParticipants received placebo SC. |
Who may qualify
- Ages
- 25 to 55 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (6 listed)
- Body mass index from 18 through 29.9 kilogram (kg)/square meter, inclusive, and weight between 50 and 100 kg, inclusive.
- QT interval corrected using Fridericia's formula ≤ 450 milliseconds (msec) for males and ≤ 470 msec for females at Screening and prior to dosing on Day 1.
- Was willing and was able to give written informed consent and complied with the study visit schedule.
- Documented vaccination with tetravalent meningococcal conjugate vaccine at least 56 days and not more than 3 years prior to dosing. Documentation must have included a positive serum bactericidal antibody titer to confirm an immune response before study drug administration.
- Vaccination with serogroup B meningococcal vaccine at least 56 days prior to dosing on Day 1, with a booster administered at least 28 days prior to dosing on Day 1, with at least 28 days between the first and second injections.
Key exclusion criteria (31 listed)
- Participants who were in intimate and prolonged contact with (defined as living under the same roof or providing personal care to) people younger than 2 years of age or older than 65 years of age, or who were either immunocompromised or had 1 of the following underlying medical conditions: anatomic or functional asplenia (including sickle cell disease); congenital complement, properdin, factor D, or primary antibody deficiencies; acquired complement deficiencies (for example, those receiving eculizumab); or human immunodeficiency virus (HIV).
- Participants who were one of the following: professionals exposed to environments of greater risk for meningococcal disease; research, industrial, and clinical laboratory personnel routinely exposed to Neisseria meningitidis; military personnel during recruit training (military personnel could have been at increased risk of meningococcal infection when accommodated in close quarters); daycare center workers; those living on a college or university campus; and those who planned to travel during the course of the study to or had travelled to endemic areas for meningococcal meningitis (for example, India, Sub-Saharan Africa, or pilgrimage to Saudi Arabia for Hajj) within the past 6 months.
- History of any Neisseria infection.
- History of unexplained, recurrent infection, or infection requiring treatment with systemic antibiotics within 90 days prior to dosing.
- Evidence of HIV infection (HIV-1 or HIV-2 antibody titer).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| ALXN1210 SCAlso: Ravulizumab, UltomirisAll doses of ALXN1210 SC were administered by four 100-milligram (mg) SC injections of 1 milliliter (mL) each in the abdominal area. All four 1-mL injections were administered over a 15-minute period with at least 15 minutes between the end of injection in 1 participant and the start of injection in the next participant. | Drug | ALXN1210 SC |
| ALXN1210 IVAlso: Ravulizumab, UltomirisAll doses of ALXN1210 IV were administered by IV infusion, using IV sets with in-line filters, at a maximum rate of 333 mL/hour, excluding interruption for safety or technical reason. There were at least 15 minutes between the end-of-infusion/injection in 1 participant and the start-of infusion/injection in the next participant. | Drug | ALXN1210 IV |
| PlaceboAll doses of placebo SC were administered by four 100-mg SC injections of 1 mL each in the abdominal area. All four 1-mL injections were administered over a 15-minute period with at least 15 minutes between the end of injection in 1 participant and the start of injection in the next participant. | Drug | Placebo SC |
Primary outcome
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
Time frame: Baseline up to Day 200
An adverse event (AE) was defined as any unfavorable and unintended sign (for example, including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product or procedure, whether or not considered related to the medicinal product or procedure, which occurred during the course of the clinical study. TEAEs were defined as AEs with a start date or time on or after the first dose of the study drug. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.
Absolute Bioavailability of ALXN1210 SC
Time frame: Predose , end of infusion (EOI); 30 minutes post EOI; 2, 4, and 8 hours post start of infusion; and from Day 2 up to Day 150
The absolute bioavailability of ALXN1210 SC is reported as the area under the serum concentration versus time curve from time 0 extrapolated to infinity (AUCinf) geometric mean of the ALXN1210 SC group divided by the AUCinf geometric mean of the ALXN1210 IV group*100. Linear mixed model with fixed and random effects for the participant was used.
3 secondary outcomes
Percent Change From Baseline in Free Complement Protein C5 Concentration At Day 8
Time frame: Baseline, Day 8
Percent Change From Baseline In Chicken Red Blood Cell Hemolysis At Day 8
Time frame: Baseline, Day 8
Number of Participants With Positive Antidrug Antibodies (ADAs) to ALXN1210
Time frame: Baseline up to Day 200
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 May 2023.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Individual participant dataSharing planned: Yes. Alexion has a public commitment to allow requests for access to study data and will be supplying a protocol, CSR, and plain language summaries.
Related trials for Healthy
Recruiting
THE EFFECTS OF GAME-BASED EXERCISE PROGRAMS
Physical Activity, Body Image
Not yet recruitingPhase 1
A Phase I Study of GLR2053 Tablets in Chinese Healthy Adult Participants
Atopic Dermatitis
Recruiting
Colon-delivered Riboflavin and Gut Microbiota Composition
Microbiome Dysbiosis, Gut Health
Not yet recruiting
Neuroergonomic Analysis of a Brain-Computer Interface Device (BCI)
Healthy Volunteers - Male and Female
RecruitingPhase 1
First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
Healthy Volunteer, Atopic Dermatitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing ALXN1210 SC and ALXN1210 IV in people with Healthy, run by Alexion Pharmaceuticals, Inc. at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 31 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 1 May 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 1 May 2023). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) (time frame: Baseline up to Day 200). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 May 2023.